http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110840889-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94b3e3452cea93da522d25e041f55619 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-035 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-027 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473 |
| filingDate | 2019-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_443d848a9ac26c2de172f788edc3e187 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_846d200c11a47222094d6f9a830ce324 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03be435fa305f3db1c56488f27cc146b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_162ac3a2a8787882201db823cb42c26f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb45eb85e69635efb530aa55b2787a68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e347021e9e6a0c3b531dcae5ee39bf4a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17c48ac1deb333cf4196380375cf4df6 |
| publicationDate | 2020-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110840889-A |
| titleOfInvention | Construction method of animal model of Parkinson's disease |
| abstract | The invention belongs to the technical field of animal model construction, and relates to a construction method of a Parkinson's disease animal model. The construction method comprises administering to an animal an inhibitor of a type II vesicular monoamine transporter in combination with an environmental neurotoxin. In the construction method, the inhibitor of the II-type vesicular monoamine transporter and the environmental neurotoxin target VMAT2 and a mitochondrial complex I respectively, and the non-single-factor induced PD animal model is consistent with the etiology that the Parkinson disease is considered to be multi-factor induced, so that the characteristics of the human Parkinson disease can be better simulated. In the Parkinson disease animal model constructed by the DTBZ and MPTP combined drug, the dosage of MPTP is obviously lower than that used in a classical MPTP induced Parkinson disease model, on one hand, the characteristic of slow progress of human Parkinson disease can be better simulated; on the other hand, the protective agent has obvious protective effect on experimental operators, and simultaneously reduces the generation of side effects. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115517225-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112931397-A |
| priorityDate | 2019-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 85.